Healthcare
GSK is acquiring Sierra Oncology for $1.9 billion in a deal expected to help both companies take a major step in developing a treatment for rare types of cancer.
What if infants with genetic illnesses could be diagnosed in a matter of days? New research surrounding rapid whole genome sequencing suggests that soon, they could be.
The new bills result from a three-year investigation that honed in on anti-competitive efforts that have prevented generic drugs and biosimilars from entering the market.
Classical psychedelics are showing promising results in treating opioid use disorder. How they aim to do that can be found here in the article.
Shares of Biogen are falling in post-market trading after the U.S. government officially announced it will limit coverage of the company’s controversial Alzheimer’s drug Aduhelm to patients in clinical trials.
With the accelerated approval from the U.S. Food and Drug Administration, Vijoice becomes the first treatment approved in the United States for PROS
BMS partnered with digital oncology company GRYT Health to convene a series of “courageous conversations” between patients, practitioners, caregivers, clinical trial teams and public health leaders.
Alcohol use disorder is common among the population for a very long time. Adial is planning to leverage genomics that can treat pervasive alcohol use disorder.
New data from Roche’s study on the use of Ocrevus to treat patients with primary and secondary progressive multiple sclerosis demonstrated positive outcomes.
The FDA requested additional data analyses from the pediatric studies that Merck stated it has submitted. The final decision is expected on July 1, 2022.
PRESS RELEASES